**GENERIC SPECIALS - DEEP DISCOUNTS **
"Weekly Generics Campaign"
LOOK for DEEP Discounts with APCI's Weekly Generics Campaign!
Regular ordering through McKesson - discount price will be in place during campaign period.
Items on the Generics Campaign this week:
Effective for orders placed 5/28/15-6/03/15+
| ITEM# |
NDC |
DESC |
TOP 250 |
CAMPAIGN DATES |
INVOICE DATES |
| 1690502 |
17478062512 |
LATANOP 0.005% 2.5ML |
Y |
5/28/15 – 6/3/15 |
5/29/15 – 6/4/15 |
| 2026979 |
55111053405 |
DIVALPROEX ER 500MG |
Y |
5/28/15 – 6/3/15 |
5/29/15 – 6/4/15 |
| 2057974 |
378340493 |
TOLTEROD ER CAP 4MG 30 |
Y |
5/28/15 – 6/3/15 |
5/29/15 – 6/4/15 |
| 2127033 |
24208041005 |
OFLOXACIN OTIC 0.3% 5ML@ |
N |
5/28/15 – 6/3/15 |
5/29/15 – 6/4/15 |
| 1890805 |
49884060511 |
LAMOTRIG ER TAB 300MG PAR 30@ |
N |
5/28/15 – 6/3/15 |
5/29/15 – 6/4/15 |
Watch for these Items on Generics Campaign NEXT week:
| ITEM# |
NDC |
DESC |
TOP 250 |
CAMPAIGN DATES |
INVOICE DATES |
| 1345347 |
00228277911 |
PROPRAN ER 80MG |
N |
6/04/15 – 6/10/15 |
6/05/15 – 6/11/15 |
| 1941244 |
00603148158 |
NYSTATIN O/S 16OZ |
N |
6/04/15 – 6/10/15 |
6/05/15 – 6/11/15 |
| 3412673 |
00378581477 |
VALSARTAN 160 MG 90 |
N |
6/04/15 – 6/10/15 |
6/05/15 – 6/11/15 |
| 1733641 |
16714069211 |
FLUCONAZ TAB 150MG |
N |
6/04/15 – 6/10/15 |
6/05/15 – 6/11/15 |
| 1207935 |
00168005430 |
NYSTATIN CRM 10030GM |
N |
6/04/15 – 6/10/15 |
6/05/15 – 6/11/15 |
Check out a full list of APCI's Custom Discounted Items on our website - updated every Monday!
|
NEWS YOU CAN USE
|
New Launches
Generic Lotronex®
Roxane launched the generic equivalent of Lotronex® (alosetron). The Roxane item will be added to the OneStop program, with visibility in McKesson Connect Friday, May 22, 2015.
Estimated brand sales of Lotronex® are approximately $172M.
Please note, alosetron is a REMS (Risk Evaluation and Mitigation Strategy) product which will have the same REMS requirement for the prescribers of the brand product.
For your reference, the letter sent to pharmacists with additional information is included below this article in the "Documents to download" section.
Brand Item:
| Item # |
NDC |
Description |
| 2138170 |
65483089403 |
LOTRONEX TAB 0.5MG 30 |
| 2138188 |
65483089503 |
LOTRONEX TAB 1MG 30 |
There will be no ASAP/ASAP+ for this launch.
| Product Launch Information – OneStop Add |
| Bx Name |
Lotronex |
| Bx Supplier |
Prometheus |
| Generic Name |
alosetron |
| Generic Description |
alosetron tablets |
| Therapeutic Class/Indication |
A medication only for some women with severe irritable
bowel syndrome (IBS) whose main problem is diarrhea; whose IBS symptoms have
lasted 6 months or longer and have not been helped enough by other
treatments. |
| FDA Approval Date |
05/18/2015 |
| Launch Reason |
FDA Approval |
| Launch Exclusivity |
No |
| Number of Players |
1 (at this time) |
| US Brand Sales |
$172M |
To order, please use the following item number:
| Item # |
Supplier Name |
NDC |
Description |
OS ADD |
| 3455094 |
ROXANE LABORATORIES INC |
00054029513 |
Alosetron TAB 0.5MG 30 |
05/22/2015 |
| 3455110 |
ROXANE LABORATORIES INC |
00054029613 |
Alosetron TAB 1MG 30 |
05/22/2015 |
For questions please contact ISManagement@McKesson.com.
Generic Oracea®
Prasco has launched an authorized generic equivalent of Oracea® (doxycycline monohydrate).
The Prasco item will be added to the OneStop program, with visibility in McKesson Connect on Friday, May 22, 2015.
Estimated brand sales of Oracea® are approximately $525M.
Please note, Owens Labs previously launched a generic version of Oracea into the market that was not added to OneStop.
That product will be replaced by this authorized generic and will be unavailable going forward.
Brand Item:
| Item # |
NDC |
Description |
| 1891860 |
299382230 |
ORACEA CAP 30 |
There will be an ASAP/ASAP+ for this launch.
| Product Launch Information – OneStop Add |
| Bx Name |
Oracea |
| Bx Supplier |
Galderma |
| Generic Name |
doxycycline monohydrate |
| Generic Description |
DOXYCYCLINE CAP 40MG PRAS 30 |
| Therapeutic Class/Indication |
Indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients |
| FDA Approval Date |
N/A |
| Launch Reason |
Authorized Generic |
| Launch Exclusivity |
N/A |
| Number of Players |
1 |
| US Brand Sales |
$525M |
To order, please use the following item number:
| Item # |
Supplier Name |
NDC |
Description |
OS ADD |
| 3455524 |
PRASCO LABORATORIES |
66993081530 |
DOXYCYCLINE CAP 40MG PRAS 30 |
05/22/2015 |
For questions please contact ISManagement@McKesson.com.
Special Hysingla® offer from Purdue
From May 15 through August 15, 2015, Purdue will cover the full amount of the co-pay for the first Hysingla ER prescription.
The maximum quantity that may be dispensed is 30 tablets. This offer only applies to patients with commercial insurance.
For appropriate patients with commercial insurance plans that do cover Hysingla ER with a step edit or Prior Authorization, Purdue will cover the Full amount of the co-pay for the first Hysingla ER prescription.
See the Purdue Pharma page on the APCI website for more information on the current trial and savings cards.
|
APCI APPROVED VENDORS
|
New Returns Vendor: Pharmaceutical Dimensions
Benefits:
- No minimums or contract
- Free shipping
- No separating - box all items together (Prescription, Controls, OTCs, Futures and Recalls)
- Web-based system which allows you to keep track of your entire return
- Transparent detailed reporting with alalytics
- Quick payment turnaround time
CONTACT INFO:
Kana M. Knollmeyer
Sales Manager
kknollmeyer@phdreturns.com
mobile: 336-337-2410
toll free: 877-297-4851
fax: 336-664-5289
http://www.phdreturns.com/